A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours

Por Dredge, Keith, Brennan, Todd V., Hammond, Edward, Lickliter, Jason D., Lin, Liwen, Bampton, Darryn, Handley, Paul, Lankesheer, Fleur, Morrish, Glynn, Yang, Yiping, Brown, Michael P., Millward, Michael
Publicado no Br J Cancer (2018)

Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials

Por Beran, Jiři, Lickliter, Jason D, Schwarz, Tino F, Johnson, Casey, Chu, Laurence, Domachowske, Joseph B, Van Damme, Pierre, Withanage, Kanchanamala, Fissette, Laurence A, David, Marie-Pierre, Maleux, Koen, Schmidt, Alexander C, Picciolato, Marta, Dieussaert, Ilse
Publicado no J Infect Dis (2018)

Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600–mutant tumours

Por Nebot, Noelia, Arkenau, Hendrik‐Tobias, Infante, Jeffrey R., Chandler, Jason C., Weickhardt, Andrew, Lickliter, Jason D., Sarantopoulos, John, Gordon, Michael S., Mak, Gabriel, St‐Pierre, Annie, Tang, Lihua, Mookerjee, Bijoyesh, Carson, Stanley W., Hayes, Siobhan, Grossmann, Kenneth F.
Publicado no Br J Clin Pharmacol (2018)

ELK4 neutralization sensitizes glioblastoma to apoptosis through downregulation of the anti-apoptotic protein Mcl-1

Por Day, Bryan W., Stringer, Brett W., Spanevello, Mark D., Charmsaz, Sara, Jamieson, Paul R., Ensbey, Kathleen S., Carter, Jacinta C., Cox, Joanne M., Ellis, Vicky J., Brown, Christopher L., Walker, David G., Inglis, Po L., Allan, Suzanne, Reynolds, Brent A., Lickliter, Jason D., Boyd, Andrew W.
Publicado em 2011